GO:0043392 negative regulation of DNA binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0043392 (negative regulation of DNA binding) describes any process that reduces the frequency, rate, or extent of selective DNA binding by a gene product [1,3,8].
• This regulation is essential for controlling transcription factor activity, as shown for CREB, thyroid hormone receptor, and bacterial response regulators [1,4,5,7].
• Key mechanisms include ligand-induced conformational changes, protein-protein interactions, and post-translational modifications that mask or alter DNA-binding domains [1,3,8].
• Dysregulation of DNA-binding inhibition is linked to cancer, metabolic disorders, and developmental defects [1,4,6].
• CRISPR knockout, point mutation, knock-in, and overexpression models enable precise dissection of these regulatory processes [1,3,5].
• EDITGENE provides end-to-end services to generate and screen such models, accelerating functional validation of DNA-binding regulators.
Description
The Gene Ontology term GO:0043392, negative regulation of DNA binding, defines any process that stops or reduces the frequency, rate, or extent of DNA binding, where DNA binding is the selective interaction of a gene product with DNA [1,3,8]. This regulatory process is fundamental to controlling gene expression, because many transcription factors must bind DNA to exert their effects, and their activity is often modulated by inhibitors or conformational changes that prevent DNA engagement [1,4,7]. For researchers, understanding negative regulation of DNA binding is critical for deciphering how cells respond to stress, hormones, and metabolic cues [1,4,7]. For example, CREB DNA binding activity is tunably regulated in response to genotoxic stress, linking DNA-binding control to metabolism. Similarly, thyroid hormone receptor DNA binding is required for both positive and negative gene regulation, and its inhibition is a key aspect of hormone action [4,7]. In bacteria, regulators such as BpsR and QseB undergo ligand-induced changes that reduce DNA binding, controlling biofilm formation and virulence [3,5]. Thus, GO:0043392 encompasses diverse molecular strategies that fine-tune DNA-protein interactions across all domains of life.
negative regulation of DNA binding At A Glance
| GO ID | GO:0043392 |
|---|---|
| GO term | negative regulation of DNA binding |
| Ontology | biological_process |
| Synonym | down regulation of DNA binding, down-regulation of DNA binding, downregulation of DNA binding, inhibition of DNA binding |
| Major function | Reduces the frequency, rate, or extent of selective DNA binding by a gene product |
| Related processes | Regulation of transcription, signal transduction, stress response, metabolism |
| Example regulators | CREB, thyroid hormone receptor, BpsR, QseB, lac repressor, Id proteins |
| Disease relevance | Cancer, metabolic disorders, developmental defects, bacterial infections |
What Is GO:0043392?
Negative regulation of DNA binding (GO:0043392) refers to any biological process that decreases the frequency, rate, or extent of DNA binding, where DNA binding is defined as the selective interaction of a gene product with DNA [1,3,8]. This includes mechanisms such as inhibitor proteins that sequester transcription factors, ligand binding that induces conformational changes preventing DNA contact, and post-translational modifications that alter the DNA-binding domain [1,3,8]. The term is a biological process and is not restricted to a specific gene or organism; it applies whenever a regulatory event reduces DNA-binding activity [1,4,5].
Why Is negative regulation of DNA binding Important in Cell Biology?
Negative regulation of DNA binding is crucial because it provides a rapid and reversible way to control gene expression without altering protein abundance. By inhibiting DNA binding, cells can quickly respond to environmental changes, such as genotoxic stress or hormonal signals, as demonstrated for CREB and thyroid hormone receptor [1,4,7]. In bacteria, this regulation controls biofilm formation and virulence, making it a target for antimicrobial strategies [3,5]. Moreover, defects in DNA-binding inhibition can lead to uncontrolled transcription factor activity, contributing to cancer and other diseases [1,6]. Therefore, studying GO:0043392 is essential for understanding normal physiology and developing therapeutic interventions.
• Controls transcription factor activity in response to stress and hormones [1,4,7].
• Regulates metabolic gene expression through CREB DNA binding modulation.
• Mediates thyroid hormone action by inhibiting or enabling receptor DNA binding [4,7].
• Governs bacterial biofilm formation and virulence via regulators like BpsR and QseB [3,5].
• Influences neural cell proliferation and differentiation through inhibitors of DNA binding.
• Provides a mechanism for rapid, reversible gene regulation without protein degradation [1,8].
• Dysregulation is associated with cancer, metabolic syndrome, and developmental disorders [1,6].
• Offers targets for antibacterial and anticancer drug development [3,5].
• Enables fine-tuning of gene expression in synthetic biology and CRISPR screens [1,3].
• Essential for understanding basic DNA-protein interaction dynamics.
What Happens During negative regulation of DNA binding?
Ligand-induced conformational changes
In simple terms: A small molecule binds to a protein and changes its shape so it can no longer grab DNA.
Many DNA-binding proteins are regulated by ligands that induce conformational changes. For example, BpsR from Bordetella undergoes a structural rearrangement upon binding 6-hydroxynicotinic acid, which reduces its DNA-binding affinity and controls biofilm formation. Similarly, the lac repressor binds allolactose, causing a conformational shift that prevents DNA binding and induces the lac operon. These examples illustrate how ligand binding can negatively regulate DNA binding.
Protein-protein interactions with inhibitors
In simple terms: Another protein sticks to the DNA-binding protein and blocks it from touching DNA.
Inhibitor proteins can sequester transcription factors and prevent DNA binding. The Id proteins (inhibitors of DNA binding) heterodimerize with basic helix-loop-helix transcription factors, preventing them from binding DNA and regulating neural cell proliferation and differentiation. This mechanism is critical for developmental processes and is conserved across species.
Post-translational modifications
In simple terms: Chemical tags added to a protein can interfere with its ability to bind DNA.
Phosphorylation, acetylation, and other modifications can alter the DNA-binding domain or its accessibility. For instance, CREB DNA binding activity is tunably regulated in response to genotoxic stress, involving changes in phosphorylation that affect its interaction with DNA. Such modifications provide a dynamic switch for negative regulation.
Competition with other DNA-binding proteins
In simple terms: A different protein competes for the same DNA site, kicking off the original protein.
Competition for DNA binding sites can effectively reduce the binding of a specific factor. In yeast, RAP1 homologues show differences in DNA binding and telomere length regulation, indicating that competitive interactions contribute to negative regulation. This mechanism is common in gene regulatory networks.
Regulation of DNA binding by thyroid hormone receptor
In simple terms: Thyroid hormone receptor needs to bind DNA to regulate genes, but its binding can be inhibited.
Thyroid hormone receptor DNA binding is required for both positive and negative gene regulation, and its activity is modulated by hormone binding and coregulators [4,7]. Negative regulation of DNA binding in this context is essential for proper metabolic and developmental responses.
Key Genes Involved in GO:0043392 negative regulation of DNA binding
The following genes and proteins are experimentally validated regulators or effectors of negative regulation of DNA binding (GO:0043392).
| Gene | Major Role | Research Relevance |
|---|---|---|
| CREB1 | Transcription factor whose DNA binding is tunably regulated under genotoxic stress | Links stress response to metabolism; target for cancer and metabolic studies |
| THRB | Thyroid hormone receptor; DNA binding required for positive and negative gene regulation | Mediates thyroid hormone action; mutations cause resistance to thyroid hormone [4,7] |
| BpsR | Bordetella response regulator; ligand-induced reduction of DNA binding | Controls biofilm formation; model for ligand-regulated DNA binding |
| QseB | Francisella tularensis response regulator; DNA-binding motif and regulation | Virulence regulation; target for antibacterial development |
| KdpE | Two-component response regulator; DNA-binding mechanisms | Osmotic stress response; model for signal transduction |
| BfpR | Francisella tularensis response regulator; DNA-binding regulation | Biofilm and virulence; potential drug target |
| ID1 | Inhibitor of DNA binding; heterodimerizes with bHLH factors | Neural proliferation and differentiation; cancer stemness |
| ID2 | Inhibitor of DNA binding; blocks bHLH transcription factors | Developmental processes; tumorigenesis |
| ID3 | Inhibitor of DNA binding; regulates cell cycle and differentiation | Neurogenesis and cancer |
| ID4 | Inhibitor of DNA binding; involved in neural and mammary development | Breast cancer and stem cell biology |
| LacI | Lac repressor; allolactose-induced conformational change prevents DNA binding | Classic model for allosteric regulation of DNA binding |
| RAP1 | Yeast telomere regulator; DNA binding and telomere length control | Telomere biology and aging |
| NR3C1 | Glucocorticoid receptor; DNA binding regulated by ligand and chaperones | Stress response and inflammation [1,4] |
| TP53 | Tumor suppressor; DNA binding regulated by post-translational modifications | Cancer biology and DNA damage response |
| NFKB1 | Transcription factor; DNA binding inhibited by IκB proteins | Inflammation and immune regulation |
| MYC | Oncogene; DNA binding modulated by partner proteins | Cancer and cell cycle |
| JUN | AP-1 component; DNA binding regulated by phosphorylation | Stress response and proliferation |
| FOS | AP-1 component; DNA binding affected by dimerization | Immediate early gene regulation |
How Is negative regulation of DNA binding Regulated?
Negative regulation of DNA binding is itself tightly regulated by various signaling pathways. For example, genotoxic stress triggers CREB DNA binding activity changes that couple stress response to metabolism. Thyroid hormone levels modulate thyroid hormone receptor DNA binding, which is required for both positive and negative gene regulation [4,7]. In bacteria, two-component systems respond to environmental signals to regulate DNA binding of response regulators like QseB and KdpE. Additionally, inhibitor proteins such as Id are regulated by growth factors and differentiation cues. These layers of regulation ensure that DNA binding is appropriately suppressed or activated in response to cellular needs.
negative regulation of DNA binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ID1 | Cancer, neural differentiation | Knockout and overexpression in neural stem cells |
| THRB | Resistance to thyroid hormone | Point mutation knock-in in mice [4,7] |
| CREB1 | Metabolic disorders, cancer | Knockout and phospho-mutant knock-in |
| BpsR | Bordetella biofilm formation | Bacterial knockout and ligand-binding assays |
| QseB | Francisella tularensis virulence | Knockout and DNA-binding assays |
Cancer
Dysregulation of DNA-binding inhibitors can lead to uncontrolled transcription factor activity. For instance, Id proteins are overexpressed in many cancers and promote proliferation by sequestering bHLH factors, preventing their DNA binding. CREB DNA binding activity is linked to genotoxic stress response and metabolism, and its misregulation may contribute to cancer cell survival. Targeting negative regulation of DNA binding is a potential therapeutic strategy.
Metabolic disorders
CREB DNA binding activity couples genotoxic stress response and metabolism, and its tunable regulation is important for metabolic homeostasis. Thyroid hormone receptor DNA binding is required for both positive and negative gene regulation, and mutations affecting this process cause resistance to thyroid hormone, a metabolic disorder [4,7].
Infectious diseases
Bacterial pathogens use negative regulation of DNA binding to control virulence and biofilm formation. BpsR in Bordetella reduces DNA binding upon ligand binding, affecting biofilm formation. In Francisella tularensis, response regulators QseB, KdpE, and BfpR regulate DNA binding to control virulence. Inhibiting these processes could be a novel antibacterial strategy.
Neurological disorders
Inhibitors of DNA binding (Id proteins) regulate neural cell proliferation and differentiation, and their dysregulation is implicated in neurodevelopmental disorders and brain tumors. Understanding how Id proteins negatively regulate DNA binding may provide insights into neural regeneration and disease.
From negative regulation of DNA binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ID1 increase DNA binding of bHLH factors? | ID1 knockout cell line |
| How does CREB phosphorylation affect DNA binding? | Point mutation knock-in of CREB at phospho-sites |
| Does thyroid hormone receptor DNA binding inhibition affect gene regulation? | THRB knockout and point mutation knock-in [4,7] |
| Can ligand binding to BpsR be blocked? | BpsR overexpression and point mutation |
| What is the role of QseB DNA binding in virulence? | QseB knockout in Francisella |
| How do Id proteins regulate neural differentiation? | Inducible overexpression of ID1 in neural cells |
How to Study the negative regulation of DNA binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| EMSA | Direct DNA binding activity in vitro | Assessing effect of inhibitors on CREB |
| ChIP-qPCR | In vivo DNA occupancy at specific loci | Thyroid hormone receptor binding |
| ChIP-seq | Genome-wide DNA binding sites | Mapping QseB binding in Francisella |
| Luciferase reporter | Transcriptional output of DNA binding | Thyroid hormone receptor function |
| CRISPR knockout screen | Genes affecting DNA binding | Identifying negative regulators |
| Surface plasmon resonance | Binding kinetics and affinity | BpsR-ligand interactions |
| Isothermal titration calorimetry | Thermodynamics of DNA-protein binding | Lac repressor-allolactose |
| Proteomics | Protein interactions and modifications | Id protein complexes |
Electrophoretic mobility shift assay (EMSA)
EMSA is a classic method to measure DNA binding activity. It can be used to assess the effect of negative regulators by incubating purified proteins or nuclear extracts with labeled DNA probes. For example, CREB DNA binding activity was measured using EMSA under genotoxic stress. This method is quantitative and can detect changes in binding affinity.
Chromatin immunoprecipitation (ChIP)
ChIP allows detection of DNA binding in vivo. By crosslinking cells and immunoprecipitating the protein of interest, researchers can quantify its occupancy on target genes. This is useful for studying negative regulation of DNA binding by inhibitors or modifications [1,4].
Reporter assays
Transcriptional reporter assays can indirectly measure DNA binding by monitoring the expression of a reporter gene under the control of a promoter containing the binding site. This is widely used for thyroid hormone receptor and CREB studies [4,7].
CRISPR screens
Genome-wide CRISPR knockout or activation screens can identify genes that negatively regulate DNA binding. For example, a screen for regulators of CREB DNA binding could reveal novel inhibitors. These screens are powerful for unbiased discovery.
How CRISPR Can Be Used to Study GO:0043392 negative regulation of DNA binding
Knockout
CRISPR knockout is used to delete genes that negatively regulate DNA binding, such as ID1 or BpsR, to observe increased DNA binding of their targets. For example, knocking out ID1 in neural cells can lead to enhanced bHLH DNA binding and altered differentiation. In bacteria, knockout of BpsR can affect biofilm formation.
Point Mutation
Point mutations can be introduced to disrupt specific regulatory sites, such as phosphorylation sites in CREB or ligand-binding residues in BpsR, to test their role in negative regulation of DNA binding [1,3]. This allows precise structure-function analysis.
Knock-in
Knock-in of tagged or mutant versions of genes, such as a fluorescently tagged thyroid hormone receptor, enables live-cell imaging and ChIP studies to track DNA binding dynamics [4,7]. Knock-in of disease-associated mutations can model resistance to thyroid hormone.
Overexpression
Overexpression of negative regulators like Id proteins or BpsR can suppress DNA binding of target transcription factors, providing a gain-of-function approach to study downstream effects [6,3]. This is useful for validating inhibitor function.
How EDITGENE Supports negative regulation of DNA binding Research
Researchers studying negative regulation of DNA binding-related genes often need to determine whether a candidate gene is causally involved in controlling DNA binding activity. EDITGENE provides comprehensive CRISPR-based services to generate knockout, point mutation, knock-in, and overexpression cell models, as well as library screening and bioinformatics support, to accelerate functional validation.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of DNA binding research.
Frequently Asked Questions About negative regulation of DNA binding
What is negative regulation of DNA binding (GO:0043392)?
It is any process that reduces the frequency, rate, or extent of selective DNA binding by a gene product, as defined by the Gene Ontology [1,3,8].
What genes are involved in negative regulation of DNA binding?
Key genes include CREB1, THRB, ID1-4, BpsR, QseB, KdpE, BfpR, LacI, and RAP1, among others [1,2,3,4,5,6,8].
How does negative regulation of DNA binding work?
Mechanisms include ligand-induced conformational changes, protein-protein interactions with inhibitors, post-translational modifications, and competition for DNA sites [1,3,6,8].
Why is negative regulation of DNA binding important?
It allows rapid control of gene expression in response to stress, hormones, and environmental signals, and its dysregulation is linked to cancer, metabolic disorders, and infections [1,4,6].
What diseases are associated with defects in negative regulation of DNA binding?
Cancer, metabolic disorders like resistance to thyroid hormone, neurological disorders, and bacterial infections [1,4,5,6].
How can I study negative regulation of DNA binding?
Use EMSA, ChIP, reporter assays, and CRISPR screens to measure DNA binding and identify regulators [1,4,5].
What model systems are used to study GO:0043392?
Cell lines with CRISPR knockout, point mutation, knock-in, or overexpression of key regulators, as well as bacterial models [1,3,5,6].
Can CRISPR be used to study negative regulation of DNA binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression are powerful tools to dissect these regulatory processes [1,3,5,6].
What is the role of CREB in negative regulation of DNA binding?
CREB DNA binding activity is tunably regulated under genotoxic stress, linking stress response to metabolism.
How does thyroid hormone receptor DNA binding relate to negative regulation?
Thyroid hormone receptor DNA binding is required for both positive and negative gene regulation, and its inhibition is a key aspect of hormone action [4,7].
Conclusion
Negative regulation of DNA binding (GO:0043392) is a fundamental biological process that controls when and where proteins interact with DNA. Through diverse mechanisms such as ligand binding, inhibitor proteins, and post-translational modifications, cells can rapidly modulate transcription factor activity to respond to internal and external cues [1,3,6,8]. This process is critical for normal development, metabolism, and immune responses, and its dysregulation contributes to cancer, metabolic disorders, and infectious diseases [1,4,5,6]. Studying GO:0043392 using CRISPR-based models and biochemical assays will continue to reveal new regulatory layers and therapeutic targets.
References
- 1. Kim SH et al.. 2016. Tunable regulation of CREB DNA binding activity couples genotoxic stress response and metabolism.. Nucleic Acids Res 44(20):9667-9680 PMID: 27431323
- 2. Wahlin J et al.. 2003. DNA binding and telomere length regulation of yeast RAP1 homologues.. J Mol Biol 332(4):821-33 PMID: 12972254
- 3. Booth WT et al.. 2019. Structural mechanism for regulation of DNA binding of BpsR, a Bordetella regulator of biofilm formation, by 6-hydroxynicotinic acid.. PLoS One 14(11):e0223387 PMID: 31697703
- 4. Wulf A et al.. 2008. The role of thyroid hormone receptor DNA binding in negative thyroid hormone-mediated gene transcription.. J Mol Endocrinol 41(1):25-34 PMID: 18562675
- 5. Gaddy KE et al.. 2024. Insights into DNA-binding motifs and mechanisms of Francisella tularensis novicida two-component system response regulator proteins QseB, KdpE, and BfpR.. Biochem Biophys Res Commun 722:150150 PMID: 38805787
- 6. Tzeng SF. 2003. Inhibitors of DNA binding in neural cell proliferation and differentiation.. Neurochem Res 28(1):45-52 PMID: 12587662
- 7. Shibusawa N et al.. 2003. Thyroid hormone receptor DNA binding is required for both positive and negative gene regulation.. J Biol Chem 278(2):732-8 PMID: 12419821
- 8. Lewis M. 2005. The lac repressor.. C R Biol 328(6):521-48 PMID: 15950160
